The U.S. Food and Drug Administration has given the green light for Mabwell Therapeutics to launch a clinical trial testing 9MW3811, its injectable treatment candidate for idiopathic pulmonary fibrosis (IPF) and cancer, according to a company press release. Last month, the National Medical Products Administration in…
News
The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed to meet its primary or secondary goals, according to recent top-line data. “The REBUILD study did not match the outcomes we…
When used in a real-world setting, Ofev (nintedanib) significantly prolonged the survival of idiopathic pulmonary fibrosis (IPF) patients, according to an analysis of Czech registry data. Yet, Ofev was not associated with a significant slowing of lung function decline or with other estimations of disease progression. Findings were…
Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis, or scarring, in a rat model of the disease. The treatment also improved lung function and extended survival in the animals, the study showed. Titled “Evaluation of Brilaroxazine (RP5063)…
Cumberland Pharmaceuticals is launching a Phase 2 clinical trial to assess the safety and efficacy of its investigational therapy, ifetroban, in treating patients with idiopathic pulmonary fibrosis (IPF). The announcement follows the U.S. Food and Drug Administration (FDA)…
Dosing is now complete in the Phase 2b GALACTIC-1 trial of GB0139 for treating idiopathic pulmonary fibrosis (IPF). The trial, which finished enrolling participants about a year ago, is testing the safety and effectiveness of the inhaled treatment candidate against a placebo among IPF patients who are…
An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…
Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring, or fibrosis, in people with idiopathic pulmonary fibrosis (IPF) — and which may be a therapeutic target to slow disease progression. The team found that these basal stem cells,…
patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases (ILDs), a group of lung diseases characterized by scarring and inflammation that includes idiopathic pulmonary fibrosis (IPF). The collaboration will harness Qureight’s artificial intelligence (AI) capability along with patientMpower’s…
Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…
